Familial facial lichen planopilaris and satisfactory response to isotretinoin

Namazi, Nastaran; Niknezhad, Nasim; Niknejad, Nakisa; Asadi-Kani, Zahra

doi:10.1111/dth.12633

Cited by 6 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LPP has been reported in three consecutive generations 4 . In a familial facial LPP, three sisters and a nephew were affected, being the only familial case in which a male was involved as in our case 5 . This is the first case report of GLPLS arising in siblings.…”

Section: Figuresupporting

confidence: 47%

Graham‐Little‐Piccardi‐Lassueur syndrome in siblings

et al. 2021

View full text Add to dashboard Cite

Section: Figuresupporting

confidence: 47%

Graham‐Little‐Piccardi‐Lassueur syndrome in siblings

et al. 2021

View full text Add to dashboard Cite

“…conducted a study on four cases of familial FFA, with typical manifestations such as facial papules, and alopecia on the frontotemporal scalp, eyebrows, and beard who went under treatment with 20 mg/day of oral isotretinoin. Three cases showed a dramatically good response to oral sotretinoin, facial lesions disappeared and perifollicular erythema and scaling was notably improved 40 …”

Section: Resultsmentioning

confidence: 96%

“…Three cases showed a dramatically good response to oral sotretinoin, facial lesions disappeared and perifollicular erythema and scaling was notably improved. 40 After obtaining informed consent form, all patients received a daily oral dose of 20 mg of isotretinoin for 6 months at the end of the trial, 68.4% of the participants showed significant improvement in clinical manifestations, classified as good or very good. 41 In another study, Saber et al conducted a prospective randomized trial on a group of 26 patients diagnosed with facial LPP.…”

Section: Facial Papules and Hairlinementioning

confidence: 99%

A review of isotretinoin in the treatment of frontal fibrosing alopecia

Shahpar,

Nezhad,

Sahaf

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

IntroductionFrontal fibrosing alopecia (FFA) is characterized by scarring alopecia of the frontotemporal scalp and facial papules. Isotretinoin is a vitamin A‐derived retinoid discovered in 1955 and approved for treating nodulocystic acne. This drug can also affect facial papules and frontotemporal hair loss in patients with FFA. In this article, we conducted a review of the available studies investigating the use of oral isotretinoin for FFA treatment. Our study provides insights into the efficacy and safety of isotretinoin as a potential treatment option for FFA and highlights areas for future research.MethodIn this study, we aimed to investigate the potential advantages and disadvantages of isotretinoin as a treatment for FFA. To identify all relevant articles, we developed a comprehensive search strategy and conducted a thorough search of three major databases: PubMed, Embase, and Science Direct. We retrieved a total of 82 articles from the search results. Two independent reviewers then screened each of the 82 articles based on our inclusion and exclusion criteria, resulting in the identification of 15 articles that were deemed relevant to our study.ResultsAcross the 15 articles, 232 patients who suffered from FFA were involved. Nearly 90% of patients experienced a significant reduction of symptoms after receiving oral isotretinoin at 10–40 mg daily. We conclude that isotretinoin can positively affect facial papules and help suppress hair loss.

show abstract

“…Three out of the four patients showed a well to isotretinoin. Of those responders one was on low‐dose isotretinoin, 20 mg/day, and 5 mg/day finasteride (Namazi, Niknezhad, Niknejad, & Asadi‐Kani, ). No clear data were found on the exact dose of isotretinoin in the rest of the patients.…”

Section: Indications Of Low‐dose Isotretinoin In Dermatologymentioning

confidence: 99%

Low dose of isotretinoin: A comprehensive review

Abdelmaksoud

Lotti

Anadolu

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Isotretinoin is a first‐generation retinoid initially approved for the treatment of severe cases of acne vulgaris (nodulocystic acne). Because of its broad anti‐inflammatory and immunomodulatory properties, it has been used beyond its initial approval in a myriad of other indications. Adverse effects of isotretinoin vary from xerosis to teratogenicity. Herein, we reviewed the literature, through date‐unlimited PubMed search, from inception till December 2019, using the following search terms: “low‐dose isotretinoin” and “dermatology,” “isotretinoin and safety,” “isotretinoin, off‐label uses,” “isotretinoin and male fertility,” “isotretinoin, iPLEDGE system,” aiming to deliver a therapeutic update relevant to clinical practice. All English‐language articles were considered with no limitation based on the articles' type. Low‐dose isotretinoin is not limited to old and novel dermatological conditions, but also showed promising results in the field of infertility and safety in the field of gastroenterology. We also highlight on the safety profile of the drug and experts' recommendations to enhance safety measures to decrease fetal risk while on isotretinoin.

show abstract

Familial facial lichen planopilaris and satisfactory response to isotretinoin

Cited by 6 publications

References 8 publications

Graham‐Little‐Piccardi‐Lassueur syndrome in siblings

Graham‐Little‐Piccardi‐Lassueur syndrome in siblings

A review of isotretinoin in the treatment of frontal fibrosing alopecia

Low dose of isotretinoin: A comprehensive review

Contact Info

Product

Resources

About